Lymphoma Flashcards
Cutaneous B cell lymphomas are lymphomas whose primary site is in the skin
True
B cell lymphomas make up a minority of NHLs whose primary site is in the skin
False, majority
What are poor prognostic factors of B cell lymphoma
Multifocal disease,
High serum level of LDH
Value of staging tumour burden in primary cutaneous MZL and primary cutaneous FCL has not been shown to have an impact on prognosis
Solitary and grouped pink to plum coloured papules, plaques or tumours — aka “Crosti’s lymphoma”
True - primary cutaneous follicle centre lymphoma
Primary cutaneous follicle centre lymphoma has recurrences up to 50% and commonly disseminates to LN or internal organs
False- Rarely disseminates
Recurrence rate correct
Nodular and diffuse infiltrates occur in parts of the dermis with PCFCL
False - in the entire dermis, deeply extending to fat
PCFCL epidermis usually involved on histo
False , usually spared
IHC of PCFCL
BCl-6 positive, CD20, CD79a, PAX-5 all positive
NEGATIVE CD5, CD43, BCl-2 —> this is a major difference to follicular lymphomas arising fro WITHIN lymph nodes
Prognosis excellent , LN/organ involvement rare w cutaneous marginal zone B cell lymphoma
True
CMZBCL can be strongly associated with scabies
False - has been linked with Borrelia and can occur in areas affected by ACRODERMATITIS chronica atrophicans
Trisomy 3 and 18 protect against CMZBCL
False- predispose
Resolution of cutaneous marginal zone B cell lymphoma can result in anetoderma
True
Cutaneous marginal zone B cell lymphoma often very tender
False - usually asymptomatic
CMZBCL often ulcerate
False - rarely
IHC of CMZBCL
CD20, CD79a, BCl-2 positive,
NEG BCl-6, CD5, CD10
Primary cutaneous large B cell lymphoma occurs exclusively in elderly patients, predominantly men
False - predominantly women
Primary cutaneous large B cell lymphoma, leg type IHC
CD20, CD79a, PAX-5, BCl-2 , MUM-1 , FOXP1
CDKN2A mutations confer a better prognosis with PCLBCL
False -worse
Intravascular diffuse large B cell lymphoma Often Present as macular erythematous and violaceous patches and plaques on trunk and thighs
False - indurated
Intravascular diffuse large B cell lymphoma IHC
Positive for BCl-2, MUM-1 , FOX-P1
Sezary syndrome triad
Circulating neoplastic T cells >1000/mcl
Erythroderma
With/without associated lymphadenopathy
Transformed MF is characterised by moprphological change of small to medium sized atypical T lymphocytes to a large cell variant
True
Need >75% of neoplastic T cell 4 x size of normal lymphocytes to diagnose large cell transformation
False, >25%
Negative prognostic factors for MF
MAFIA BEL large sezary clone 30- Male Age Folliculotropic variant Initial treatment poor response Advanced skin burden (T score)
B2 microglobulin
Eosinophilia
LDH
Large cell transformation
Sezary cell count high
Peripheral blood T cell clone detectable
CD30 neg
Extracorporeal plasmapharesis is helpful for Sezary B0-B2
True
Imiquimod is a treatment option for MF
true - 5% mon to fri for 12 weeks
Alemtuzumab is an antiCD30 drug
False anti-CD52
Folliculotropic MF displays overt epidermotropism
False - folliculotropic instead of epidermotropic
Long term follow up is necessary for LyP as risk of progression to more aggressive lymphoma eg. P C-ACL, MF or Hodgkin in 20%
False <5%
LyP spontaneously disappear over 3-8 weeks
True
SC panniculitis like T cell lymphoma occurs in the trunk>extremities
False vice versa
